Clinical Trials on Pancreatic Periampullary Cancer in Belgium

Total 1877 results

EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Recruiting

Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)

Head and Neck Cancer

United States, China, Belgium, Taiwan, Korea, Republic of, Japan, Israel, Brazil, Greece, Mexico, United Kingdom, Argentina, Austria, Czechia, France, Georgia, Germany, India, Italy, Portugal, Romania, Spain, Switzerland, Netherlands, P... and more
GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Neoplasms, Breast

United States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
Abbott

Completed

A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer

Prostate Cancer

United States, Canada, France, Spain, Belgium, Australia, United Kingdom, Italy, Sweden, South Africa, Netherlands, Ireland, Germany, Austria, New Zealand, Greece, Poland, Switzerland
Celgene

Completed

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer (Mainsail)

Prostate Cancer

United States, Spain, France, Belgium, Australia, Denmark, Austria, United Kingdom, Netherlands, Poland, Israel, Italy, Germany, Greece, Canada, Czechia, Hungary, Mexico, Russian Federation, South Africa, Sweden
Hoffmann-La Roche

Completed

A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) (MODUL)

Colorectal Cancer

Italy, Korea, Republic of, United Kingdom, Belgium, Argentina, Denmark, Greece, Netherlands, Slovenia, Spain, Sweden, Turkey, Brazil, Bosnia and Herzegovina, France, Germany, Portugal, Egypt, Poland, Slovakia, Mexico, Serbia, Russian...
Hoffmann-La Roche
Genentech, Inc.; Breast International Group

Active, not recruiting

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer (APHINITY)

Breast Cancer

United States, Belgium, Canada, Australia, Austria, Bulgaria, China, Croatia, Denmark, France, Germany, Guatemala, Hungary, Ireland, Italy, Korea, Republic of, Panama, Slovenia, Spain, Taiwan, United Kingdom, Colombia, Czechia, El Salvador and more
Nektar Therapeutics

Completed

A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine (ATTAIN)

Breast Cancer | Metastasis

United States, Australia, Belgium, Canada, France, Israel, Italy, Portugal, Spain, United Kingdom
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab (Erbitux) in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (EXTREME)

Head and Neck Cancer

France, Russian Federation, Spain, United Kingdom, Germany, Hungary, Poland, Ukraine, Austria, Netherlands, Slovakia, Sweden, Switzerland, Belgium, Italy, Portugal, Czech Republic
Bristol-Myers Squibb

Active, not recruiting

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

Melanoma | Cancer

United States, Poland, Italy, Belgium, France, Australia, Canada, Germany, Spain, Sweden, Switzerland, United Kingdom
Novartis Pharmaceuticals
NCIC Clinical Trials Group

Completed

Chemotherapy and Lapatinib or Trastuzumab in Treating Women With HER2/Neu-Positive Metastatic Breast Cancer

Breast Cancer

United States, Belgium, Canada, United Kingdom, Argentina, Australia, France, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Taiwan, Thailand, India, Korea, Republic of, Mexico, Ukraine
Novartis Pharmaceuticals

Completed

Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer (FACE)

Breast Cancer

China, United States, Belgium, Germany, Italy, Austria, Japan, Australia, Canada, Sweden, Switzerland, United Kingdom, Spain, Denmark, France, Ireland, Israel, Netherlands, Korea, Republic of, Norway
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation.

Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation

Spain, Italy, Austria, Netherlands, United Kingdom, Thailand, France, Belgium, China, Germany, Greece, Argentina, Turkey, Malaysia, Portugal, Brazil, United States, Hungary, India
Eli Lilly and Company
NSABP Foundation Inc

Active, not recruiting

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE)

Breast Cancer

United States, Spain, China, Germany, Canada, Taiwan, United Kingdom, Singapore, Italy, Australia, Japan, Hungary, Russian Federation, India, Belgium, New Zealand, Austria, Saudi Arabia, France, Czechia, Korea, Republic of, Finland, Argentin... and more
AstraZeneca
Merck Sharp & Dohme LLC; NRG Oncology; Breast International Group; Myriad Genetic... and other collaborators

Active, not recruiting

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer (OlympiA)

Breast Cancer

United States, Austria, Italy, Spain, Sweden, United Kingdom, Belgium, Poland, France, Switzerland, Canada, Germany, Korea, Republic of, Netherlands, Japan, China, Taiwan, Australia, Argentina, Israel, Hungary, Portugal, Iceland, Puerto...
Tesaro, Inc.
European Network of Gynaecological Oncological Trial Groups (ENGOT); US Oncology... and other collaborators

Completed

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

Ovarian Neoplasms | Platinum Sensitive Ovarian Cancer

United States, Belgium, Sweden, Germany, Israel, Austria, Canada, Denmark, Spain, Italy, United Kingdom, Poland, France, Hungary, Norway
AGO Research GmbH
ARCAGY/ GINECO GROUP; Australia New Zealand Gynaecological Oncology Group; Arbeitsgemeinschaft... and other collaborators

Completed

Evaluation of Optimal Treatment With Bevacizumab in Patients With Platinum-sensitive Recurrent Ovarian Cancer

Recurrent Platinum-sensitive Ovarian Cancer

France, Belgium, Germany, Australia, United Kingdom, Austria
Active Biotech AB

Completed

A Study of Tasquinimod in Men With Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer

France, Poland, Ukraine, United Kingdom, United States, China, Germany, Taiwan, Spain, Belgium, Colombia, Israel, Bulgaria, India, Panama, Romania, Netherlands, Greece, Sweden, Korea, Republic of, Australia, Canada, Chile, New Zealand, ... and more
Pfizer
Astellas Pharma Inc; Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer (PREVAIL)

Prostate Cancer

Canada, United States, Spain, Australia, Denmark, Korea, Republic of, Belgium, Singapore, Finland, Netherlands, France, Austria, Germany, Israel, United Kingdom, Italy, Japan, Lithuania, Poland, Russian Federation, Slovakia, Sweden
Pfizer
Medivation, Inc.

Completed

A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

Australia, United States, Spain, France, Korea, Republic of, Germany, Austria, United Kingdom, Belgium, Hungary, Italy, Brazil, Netherlands, Poland
Eli Lilly and Company

Completed

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Ovarian Cancer

United States, Israel, Spain, Korea, Republic of, Australia, Belgium, United Kingdom, Italy
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

Bladder Cancer

United States, Belgium, Korea, Republic of, Italy, Taiwan, China, United Kingdom, Germany, France, Argentina, Brazil, Poland, Spain, Japan, Netherlands, India, Canada, Czechia, Mexico, Australia, Portugal
Karyopharm Therapeutics Inc
GOG Foundation; Israeli Society of Gynecologic Oncology; Belgium and Luxembourg... and other collaborators

Active, not recruiting

Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO] (ENGOT-EN5)

Endometrial Cancer

United States, China, Israel, Spain, Belgium, Germany, Greece, Czechia, Italy, Canada
AstraZeneca

Recruiting

Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) (ARTEMIDE-Bil01)

Biliary Tract Cancer

France, Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Canada, Germany, Brazil, China, Japan, Taiwan, Thailand, Australia, Hong Kong, India, Denmark, Turkey, Poland, Norway
Hoffmann-La Roche

Completed

A Study of Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Bladder Cancer

United States, France, Belgium, Korea, Republic of, United Kingdom, Czechia, Austria, Canada, Denmark, Greece, Italy, Netherlands, Portugal, Slovenia, Spain, Sweden, Turkey, Poland, Hungary, Switzerland, Japan, Taiwan, Australia, Norway, Germa... and more
AstraZeneca
Daiichi Sankyo

Completed

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer (DESTINY-B12)

Breast Cancer

Denmark, Finland, Italy, Norway, Spain, Sweden, Poland, United States, Canada, Germany, Japan, Netherlands, Portugal, Switzerland, Australia, United Kingdom, Belgium, Ireland
AstraZeneca

Active, not recruiting

Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer

Ovarian Cancer

United States, Czechia, Italy, Belgium, Canada, Germany, Peru, Spain, Japan, Netherlands, United Kingdom, Australia
Exelixis

Active, not recruiting

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (STELLAR-001)

Renal Cell Carcinoma | Colorectal Cancer | Metastatic Castration-resistant Prostate Cancer | Hormone Receptor Positive Breast Carcinoma | Neoplasm Malignant

United States, Australia, Belgium, Czechia, France, Germany, Italy, Netherlands, Spain, United Kingdom
Millennium Pharmaceuticals, Inc.

Completed

Study Comparing Orteronel Plus Prednisone in Participants With Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer

Prostate Cancer

United States, France, Ukraine, United Kingdom, Belgium, Germany, Taiwan, Spain, Belarus, Israel, Portugal, Bulgaria, Romania, South Africa, Japan, Switzerland, Canada, Australia, Netherlands, Greece, Chile, New Zealand, Peru, Singapore, Russian Federation and more
ppharmaand GmbH
Bristol-Myers Squibb; Gynecologic Oncology Group; European Network of Gynaecological... and other collaborators

Active, not recruiting

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Primary Peritoneal | Newly Diagnosed | FIGO Stage III-IV | Partial Response | Complete Response

United States, United Kingdom, Korea, Republic of, Russian Federation, Canada, Denmark, Taiwan, New Zealand, Ireland, Japan, Spain, Australia, Israel, Italy, Greece, Sweden, Czechia, Finland, Poland, Belgium, Germany, Romania, Singa... and more
Hoffmann-La Roche
Genentech, Inc.

Completed

A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Participants With Metastatic Breast Cancer (MARIANNE)

Breast Cancer

United States, Italy, United Kingdom, Australia, Austria, Belgium, Brazil, Denmark, France, Guatemala, Korea, Republic of, Portugal, Spain, Turkey, Colombia, Canada, Czechia, Japan, Poland, Romania, Russian Federation, Switzerland, ... and more
Canadian Cancer Trials Group
Canadian Institutes of Health Research (CIHR); Institute of Cancer Research... and other collaborators

Active, not recruiting

Radical Versus Simple Hysterectomy and Pelvic Node Dissection With Low-risk Early Stage Cervical Cancer (SHAPE)

Cervical Cancer

Canada, France, Austria, Germany, Belgium, United Kingdom, Netherlands, China, Ireland, Norway, Russian Federation
Eli Lilly and Company
Bristol-Myers Squibb

Completed

Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer

Colorectal Cancer

United States, Australia, Austria, Belgium, Czech Republic, Finland, France, Germany, Hong Kong, Italy, Netherlands, Norway, Portugal, Slovakia, Sweden, Switzerland, United Kingdom
Boehringer Ingelheim

Recruiting

DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers

Small Cell Lung Carcinoma | Neuroendocrine Neoplasms

United States, Belgium, Spain, Korea, Republic of, United Kingdom, Germany, Japan, China, Taiwan, France, Portugal, Bulgaria
Seagen Inc.
Merck Sharp & Dohme LLC; GOG Foundation; European Network of Gynaecological Oncological... and other collaborators

Active, not recruiting

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Cervical Cancer

United States, Belgium, Netherlands, Czechia, Spain, Turkey, Ireland, United Kingdom, Italy, Denmark
Amgen
Daiichi Sankyo, Inc.

Terminated

Study of Denosumab as Adjuvant Treatment for Women With High Risk Early Breast Cancer Receiving Neoadjuvant or Adjuvant Therapy (D-CARE)

Breast Cancer

United States, Denmark, France, Italy, Belgium, Canada, Czechia, Germany, Netherlands, United Kingdom, Korea, Republic of, Peru, Philippines, Poland, Russian Federation, Taiwan, Spain, Australia, Hong Kong, Slovakia, Israel, Hungary, Portug... and more
Bayer

Completed

A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) (NEXUS)

Carcinoma, Non-Small-Cell Lung

Belgium, Spain, France, Switzerland, Greece, Italy, Hungary, Canada, Netherlands, United Kingdom, Austria, China, Israel, Mexico, Germany, Brazil, Finland, Cyprus
Sumitomo Pharma America, Inc.

Completed

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (CanStem303C)

Colorectal Cancer

United States, Canada, Spain, Australia, China, Hong Kong, Israel, Czechia, France, Japan, Belgium, Germany, Netherlands, Italy, Korea, Republic of, Singapore
Eli Lilly and Company

Completed

A Study in Second Line Metastatic Colorectal Cancer

Colorectal Cancer

United States, Germany, Italy, Spain, Romania, Taiwan, Belgium, France, Hungary, Japan, Austria, Korea, Republic of, Australia, Sweden, Netherlands, Finland, Argentina, Czechia, Brazil, Greece, India, Israel, Denmark, Portugal, Puerto Rico and more
Hoffmann-La Roche

Completed

A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer

Colorectal Cancer

United States, Belgium, Canada, China, Finland, France, Greece, Hungary, Korea, Republic of, Portugal, Spain, Thailand, United Kingdom, Australia, Germany, Israel, Singapore, Italy, Switzerland, Taiwan, New Zealand, Brazil, Hong Kong, Irelan... and more
National Cancer Institute (NCI)
Karolinska Institutet; Vanderbilt University Medical Center, USA; New England... and other collaborators

Terminated

Helicobacter Pylori Genome Project (HpGP)

Gastric Cancer | Intestinal Metaplasia | Non-Atrophic Gastritis

Spain, Lithuania, Taiwan, Singapore, Argentina, Korea, Republic of, Sweden, Canada, United States, Peru, Puerto Rico, Mexico, Chile, Turkey, Belgium, Kenya, Malaysia, Vietnam, Colombia, Israel, Brazil, Nepal, Switzerland, Japan, Congo,... and more
Egetis Therapeutics
Solasia Pharma K.K.

Terminated

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) (POLAR-M)

Colorectal Cancer | Chemotherapy-induced Peripheral Neuropathy

France, Korea, Republic of, United States, Italy, United Kingdom, Hong Kong, Spain, Hungary, Belgium, Japan, Germany, Czechia, Taiwan
Eli Lilly and Company

Completed

A Phase 3 Trial of LY900003 Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, France, Germany, Taiwan, Spain, Belgium, Switzerland, Netherlands, Russian Federation, South Africa, Poland, Hungary, Italy, Norway, India, Sweden, Argentina, United Kingdom, Puerto Rico, Chile, Romania
AstraZeneca

Terminated

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Italy, Peru, Russian Federation, Spain, Turkey, United Kingdom, Germany, China, Hungary, Latvia, Poland, Romania, Japan, Finland, Norway, Canada, South Africa, Argentina, Australia, Belgiu... and more
AstraZeneca
Merck Sharp & Dohme LLC; European Network of Gynaecological Oncological Trial... and other collaborators

Active, not recruiting

Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy

Relapsed Ovarian Cancer | Following Complete or Partial Response to Platinum Based Chemotherapy | Platinum Sensitive | BRCA Mutated

Korea, Republic of, France, China, Italy, United States, Israel, United Kingdom, Canada, Japan, Germany, Brazil, Netherlands, Belgium, Poland, Australia, Russian Federation, Spain
Novartis Pharmaceuticals

Completed

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

Metastases, Brain

Spain, Hungary, Poland, Germany, Italy, Russian Federation, Sweden, United Kingdom, Thailand, United States, Belgium, France, Greece, Denmark
AstraZeneca
RTI Health Solutions; A+A Healthcare Marketing Research; Freelance CRA (FCRA)

Completed

OSCA - Olaparib Standard of CAre Study (OSCA)

Platinum-sensitive Recurrent Serous Ovarian Cancer

France, Italy, Korea, Republic of, Spain, United Kingdom, Germany, Belgium, Israel, Portugal, Netherlands, Switzerland, Canada, Australia
AstraZeneca
European Network of Gynaecological Oncological Trial Groups (ENGOT); Myriad... and other collaborators

Active, not recruiting

Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients (DUO-O)

Advanced Ovarian Cancer

Canada, Denmark, Germany, Italy, Spain, United States, Belgium, Poland, France, Korea, Republic of, Brazil, Hungary, Japan, Peru, Turkey, China, Austria, Bulgaria, Finland, Romania
Incyte Biosciences International Sàrl

Recruiting

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Head and Neck Cancer

United States, Taiwan, Italy, Korea, Republic of, Spain, France, Portugal, Germany, Poland, Canada, Georgia, Greece, Netherlands, Belgium
AstraZeneca

Completed

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases (ENTHUSE M1)

Prostate Cancer

Sweden, United States, Brazil, Czech Republic, France, Russian Federation, United Kingdom, Germany, China, Hungary, Poland, Finland, Netherlands, Mexico, Hong Kong, Australia, Belgium, Canada, Denmark, Portugal, South Africa, Korea... and more
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)

Non-Small Cell Lung Cancer

Spain, Italy, Korea, Republic of, United States, Japan, Brazil, Taiwan, Australia, Austria, Canada, Poland, Belgium, United Kingdom, Turkey, Hungary, Germany, India

Clinical Trials on Pancreatic Periampullary Cancer in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Romania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations